ClinicalTrials.gg
CompletedNCT01480661Updated Sep 19, 2013

Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients

A Phase 4 interventional study of Roflumilast and Placebo of Roflumilast in Pulmonary Disease, Chronic Obstructive, sponsored by FLUIDDA nv. Completed at 2 sites in Belgium. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2013-09-19.

Sponsored by FLUIDDA nv · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
24th of 32
41 · median 154
Started
2011
with 4 others
Phase 4
8 of 32
1 open now
Registered
17th of 32
by date
Lead sponsor
2 of 32
FLUIDDA nv

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 24th largest by enrollment, is one of 5 that started in 2011, is one of 8 in phase 4, and was the 17th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

In this study the possible changes in airway geometry and function induced by 6 month oral treatment with Daxas® (roflumilast) will be evaluated. The use of functional respiratory imaging (FRI) on the phenotyping of chronic obstructive pulmonary disease (COPD) patients will be examined. The study population consists of 40 severe COPD patients, global initiative for chronic obstructive lung disease (GOLD) stages III until IV.

Imaging parameters will be assessed and the correlation with lung function and health related quality of life will be checked before and after treatment.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Pulmonary Disease, Chronic Obstructive
  • Computed Tomography scan
  • Functional Respiratory Imaging
  • Roflumilast
  • Health Related Quality of Life
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient ≥ 30 years old
  • Patient with ≥ 20
  • Written obtained
  • Female patient of who confirm that a method was used at least 14 days before visit 1 and will continue to use a contraception method during the study.
  • Patient should be treated according to GOLD guidelines
  • patient with GOLD stages III until IV
  • Patient with smoking history of at least 10 pack-years
  • Patient takes Spiriva® and a fixed combination of inhaled and long acting beta agonist (LABA) at least 6 weeks before visit 1
  • Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Patient with severe immunological diseases and/ or severe acute infectious diseases.
  • Patient with heart failure
  • Patient with diagnosis of cancer (except basal cell carcinoma)
  • Patient with a history of depression associated with suicidal ideation or behaviour
  • Patient with moderate or severe hepatic impairment.
  • Patient with lactose intolerance
  • Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
  • Patient who received any new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    Roflumilast

    Drug: Roflumilast · Radiation: Functional Respiratory Imaging

  • Placebo comparator
    Placebo

    Drug: Placebo of Roflumilast · Radiation: Functional Respiratory Imaging

Interventions

  • Roflumilast 500 µg, once a day in the morning during 6 months

    Also known as: Daxas®

  • DrugPlacebo of Roflumilast

    Placebo 500 µg, once a day in the morning during 6 months

  • RadiationFunctional Respiratory Imaging

    CT scan of thorax, at baseline and after 6 months

06

What researchers measure

Primary outcomes

  1. Changes in airway geometry and function using CT based functional respiratory imaging.

    The primary objective of this study is to evaluate the possible use of CT based functional respiratory imaging (CT-FRI) on the phenotyping of severe COPD patients after a 6 month treatment with Daxas®.

    Time frame: At baseline and after 6 months of treatment

Secondary outcomes

  1. Lung function tests (spirometry, bodyplethysmography, diffusion capacity, forced oscillation technique)

    Imaging parameters will be assessed and the correlation with lung function will be checked before and after treatment.

    Time frame: At baseline and after 6 months of treatment

  2. Health related quality of life

    Imaging parameters will be assessed and the correlation with health related quality of life will be checked before and after treatment.

    Time frame: At baseline and after 6 months of treatment

07

Study locations

2 sites
  • Antwerp University Hospital
    Edegem, Antwerp 2650, Belgium
  • ZNA Middelheim
    Antwerp, 2020, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2011
First posted
Nov 29, 2011
Start
Dec 2011
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
Sep 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01480661
Lead sponsor
FLUIDDA nv
Responsible party
Sponsor
First posted
Nov 29, 2011
Start date
Dec 2011
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Sep 19, 2013

Study contacts

Wilfried De Backer, MD, PhD
principal investigator · University Hospital, Antwerp
Lieven Bedert, MD
principal investigator · ZNA Middelheim

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion